These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34486009)

  • 41. Prodrugs of hydrogen sulfide and related sulfur species: recent development.
    Yuan ZN; Zheng YQ; Wang BH
    Chin J Nat Med; 2020 Apr; 18(4):296-307. PubMed ID: 32402407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine.
    Chatzisideri T; Leonidis G; Karampelas T; Skavatsou E; Velentza-Almpani A; Bianchini F; Tamvakopoulos C; Sarli V
    J Med Chem; 2022 Jan; 65(1):271-284. PubMed ID: 34967607
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficient Click Synthesis of a Protonized and Reduction-Sensitive Amphiphilic Small-Molecule Prodrug Containing Camptothecin and Gemcitabine for a Drug Self-Delivery System.
    Dong S; He J; Sun Y; Li D; Li L; Zhang M; Ni P
    Mol Pharm; 2019 Sep; 16(9):3770-3779. PubMed ID: 31348660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
    Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
    Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
    Wang F; Zhang Z
    Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway.
    Pei Q; Pan J; Ding X; Wang J; Zou X; Lv Y
    Pancreatology; 2015; 15(3):233-9. PubMed ID: 25937078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
    Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
    ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6C
    Wu C; Tan X; Hu X; Zhou M; Yan J; Ding C
    J Immunol; 2020 Jan; 204(1):212-223. PubMed ID: 31776206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monogalactosyl diacylglycerol, a replicative DNA polymerase inhibitor, from spinach enhances the anti-cell proliferation effect of gemcitabine in human pancreatic cancer cells.
    Akasaka H; Sasaki R; Yoshida K; Takayama I; Yamaguchi T; Yoshida H; Mizushina Y
    Biochim Biophys Acta; 2013 Mar; 1830(3):2517-25. PubMed ID: 23174220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine.
    Dubey RD; Alam N; Saneja A; Khare V; Kumar A; Vaidh S; Mahajan G; Sharma PR; Singh SK; Mondhe DM; Gupta PN
    Int J Pharm; 2015 Aug; 492(1-2):80-91. PubMed ID: 26165611
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.
    Pei Q; Pan J; Zhu H; Ding X; Liu W; Lv Y; Zou X; Luo H
    Int Immunopharmacol; 2014 Mar; 19(1):10-6. PubMed ID: 24389382
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gemcitabine-loaded gold nanospheres mediated by albumin for enhanced anti-tumor activity combining with CT imaging.
    Wang Z; Chen L; Chu Z; Huang C; Huang Y; Jia N
    Mater Sci Eng C Mater Biol Appl; 2018 Aug; 89():106-118. PubMed ID: 29752079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules.
    Stella B; Arpicco S; Rocco F; Marsaud V; Renoir JM; Cattel L; Couvreur P
    Int J Pharm; 2007 Nov; 344(1-2):71-7. PubMed ID: 17651931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug.
    Maiti S; Park N; Han JH; Jeon HM; Lee JH; Bhuniya S; Kang C; Kim JS
    J Am Chem Soc; 2013 Mar; 135(11):4567-72. PubMed ID: 23461361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
    Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
    Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A facile di-acid mono-amidation strategy to prepare cyclization-activating mono-carboxylate transporter 1-targeting gemcitabine prodrugs for enhanced oral delivery.
    Wang Y; Wang G; Chen H; Sun Y; Sun M; Liu X; Jian W; He Z; Sun J
    Int J Pharm; 2020 Jan; 573():118718. PubMed ID: 31756441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
    Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
    Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.
    Pratt SE; Durland-Busbice S; Shepard RL; Heinz-Taheny K; Iversen PW; Dantzig AH
    Clin Cancer Res; 2013 Mar; 19(5):1159-68. PubMed ID: 23325581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypoxia-Activated and Indomethacin-Mediated Theranostic Prodrug Releasing Drug On-Demand for Tumor Imaging and Therapy.
    Peng X; Gao J; Yuan Y; Liu H; Lei W; Li S; Zhang J; Wang S
    Bioconjug Chem; 2019 Nov; 30(11):2828-2843. PubMed ID: 31592652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.